TY - JOUR
T1 - Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression
AU - Park, Yong
AU - Kang, Myoung Hee
AU - Seo, Hee Yeon
AU - Park, Joong Min
AU - Choi, Chul Won
AU - Kim, Yeul Hong
AU - Kim, In Sun
AU - Kim, Jun Suk
AU - Oh, Sang Cheul
N1 - Funding Information:
Acknowledgment This work was supported by the Korea Research Foundation Grant funded by the Korean Government (KRF-2008-331-E00470) and the Korea University Grant. All authors reported that there was no conflict of interests in this study.
PY - 2010/12
Y1 - 2010/12
N2 - Bone morphogenetic protein-2 (BMP-2) was reported to enhance migration, invasion, and metastasis at the various types of cancer cells. The purpose of this study is to identify the role of BMP-2 in progression of gastric cancer. Forty-four patients with operable gastric cancer were enrolled. Also, twenty healthy volunteers were enrolled as control group. All patients received gastrectomy with D2 lymphadenectomy, and surgical staging was performed. Whole blood was obtained preoperatively in all patients, and serum BMP-2 levels were quantified by commercially available ELISA kit. Immunohistochemical stain for BMP-2 in all gastric cancer tissues was performed using tissue microarray. All patients showed increased serum BMP-2 levels compared with control group, when upper normal limit was defined as the mean of control serum level + 2 × standard deviation. The mean serum BMP-2 level of lymph node positive group was significantly elevated than that of lymph node-negative group (382.7 pg/ml, 95% CI 341.99-423.4 pg/ml vs 211.69 pg/ml, 95% CI 191.09-232.29 pg/ml, P < 0.001). The serum BMP-2 was strongly correlated with the depth of invasion (T stage) and the extent of regional lymph node involvement (N stage) (r = 0.662, P < 0.001 and r = 0.831, P < 0.001, respectively). Moreover, the serum BMP-2 was correlated with the grade of tumor histology(r = 0.421, P = 0.008). Immunohistochemical stain showed the specific expression of BMP-2 in cancer cells compared with normal gastric mucosa. In conclusion, serum BMP-2 is associated with progression from early localized gastric cancer to locally advanced gastric cancer.
AB - Bone morphogenetic protein-2 (BMP-2) was reported to enhance migration, invasion, and metastasis at the various types of cancer cells. The purpose of this study is to identify the role of BMP-2 in progression of gastric cancer. Forty-four patients with operable gastric cancer were enrolled. Also, twenty healthy volunteers were enrolled as control group. All patients received gastrectomy with D2 lymphadenectomy, and surgical staging was performed. Whole blood was obtained preoperatively in all patients, and serum BMP-2 levels were quantified by commercially available ELISA kit. Immunohistochemical stain for BMP-2 in all gastric cancer tissues was performed using tissue microarray. All patients showed increased serum BMP-2 levels compared with control group, when upper normal limit was defined as the mean of control serum level + 2 × standard deviation. The mean serum BMP-2 level of lymph node positive group was significantly elevated than that of lymph node-negative group (382.7 pg/ml, 95% CI 341.99-423.4 pg/ml vs 211.69 pg/ml, 95% CI 191.09-232.29 pg/ml, P < 0.001). The serum BMP-2 was strongly correlated with the depth of invasion (T stage) and the extent of regional lymph node involvement (N stage) (r = 0.662, P < 0.001 and r = 0.831, P < 0.001, respectively). Moreover, the serum BMP-2 was correlated with the grade of tumor histology(r = 0.421, P = 0.008). Immunohistochemical stain showed the specific expression of BMP-2 in cancer cells compared with normal gastric mucosa. In conclusion, serum BMP-2 is associated with progression from early localized gastric cancer to locally advanced gastric cancer.
KW - Bone morphogenetic protein 2
KW - Enzyme-linked immunosorbent assay
KW - Immunohistochemistry
KW - Neoplasm invasiveness
KW - Stomach neoplasm
KW - Tumorigenesis
UR - http://www.scopus.com/inward/record.url?scp=77954031283&partnerID=8YFLogxK
U2 - 10.1007/s12032-009-9358-x
DO - 10.1007/s12032-009-9358-x
M3 - Article
C2 - 19924575
AN - SCOPUS:77954031283
VL - 27
SP - 1192
EP - 1199
JO - Medical oncology (Northwood, London, England)
JF - Medical oncology (Northwood, London, England)
SN - 1357-0560
IS - 4
ER -